Atai’s pipeline is designed to transform mental health care. Key assets include VLS-01 (DMT-based for treatment-resistant depression), EMP-01 (MDMA-based for social anxiety), and novel non-hallucinogenic 5-HT2A receptor agonists. With convenient administration methods and short in-clinic times, Atai is positioning itself as a market leader in next-gen psychedelic medicine.Based in both Berlin, Germany and the Netherlands, Atai Life Sciences is pushing the boundaries of mental health treatment. This clinical ...

Investors might want to bet on atai Life Sciences N.V. (ATAI) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years. ...

My name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens, OH, USA, a graduate degree in Business Management from Universidad Andina Simon Bolivar, Quito, Ecuador, and the Ph.D. degree in computer applications from the University of Alicante, Spain.Disclosure: I collaborate professionally with Edgar Torres H, who is also an author on Seeking ...

Group 1 - The article does not provide any specific company or industry analysis, focusing instead on the author's qualifications and disclosures [1][2][3]

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2][3] - The news team covers key finance and investing hubs including London, New York, Toronto, Vancouver, Sydney, and Perth [2] - Proactive focuses on medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [2][3] Group 2 - The team delivers news and insights across various sectors including biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] - Proactive adopts technology to enhance workflows and improve content production [4][5] - All content published by Proactive is edited and authored by humans, ensuring adherence to best practices in content production and search engine optimization [5]

Core Insights - Proactive provides fast, accessible, and actionable business and finance news content to a global investment audience [2] - The company focuses on medium and small-cap markets while also covering blue-chip companies and broader investment stories [3] - Proactive's news team delivers insights across various sectors including biotech, mining, oil and gas, and emerging technologies [3] Technology Adoption - Proactive is committed to adopting technology to enhance workflows and content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Breakthrough Therapy designation recognizes the potential of BPL-003 to deliver substantial improvement over existing therapies for patients with treatment-resistant depressionFDA designation follows previously announced Phase 2b topline data which showed rapid and durable antidepressant outcomes following a single dose of BPL-003Breakthrough Therapy designation provides intensive FDA guidance to support advancement of BPL-003 NEW YORK and AMSTERDAM, Oct. 16, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NAS ...

Needham on Monday initiated coverage on Atai Life Sciences NV (NASDAQ:ATAI), a clinical-stage biopharmaceutical company focused on developing treatments for mental health.The company’s lead drug candidate, BPL-003, is under development for treatment-resistant depression. • ATAI stock is gaining positive traction. See what is happening here.Topline results from the eight-week core phase of the Phase 2b study met its primary and all key secondary endpoints, and BPL-003 demonstrated rapid, robust and durable a ...

DoorDash Trade - Ark Invest significantly increased its stake in DoorDash by purchasing 25,581 shares, amounting to approximately $7.2 million, with the stock closing at $281.74, a 3.88% increase [2] - This purchase followed the announcement of a multi-year partnership with Criteo S.A. to enhance advertising opportunities on DoorDash's platform, aiming to capitalize on the growth of retail media [3] Alibaba Trade - Ark Invest acquired 4,449 shares of Alibaba, valued at around $832,000, with the stock closing at $187.22 [4] - Alibaba's stock has gained over 120% year-to-date, driven by its focus on cloud computing and artificial intelligence [4] - Ark Invest has been consistently buying Alibaba shares, with recent purchases totaling $2.74 million, $5.5 million, and $4.1 million over the past week [5] Brera Holdings Trade - Ark Invest reduced its stake in Brera Holdings by selling 54,400 shares, valued at roughly $1.2 million, with the stock closing at $21.91, down 11.94% [6] - The stock had previously surged by 225% due to its Solana Treasury Strategy but has since experienced a pullback [6] Rocket Lab Trade - Ark Invest sold 86,326 shares of Rocket Lab Corp, valued at nearly $5 million, with the stock closing at $58.50, up by 4.17% [8] - Rocket Lab announced a multi-launch contract with Synspective, adding 10 more launches to its portfolio, indicating its growing presence in the satellite launch market [8] Other Key Trades - Ark Invest purchased 1,740 shares of MercadoLibre Inc. and sold 180,169 shares of Adaptive Biotechnologies Corp [9] - Additionally, Ark bought 254,642 shares of ATAI Life Sciences NV and acquired shares of L3Harris Technologies Inc. [11]

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) chief scientific officer Glenn Short spoke with Proactive about the company’s recent NIH grant and its innovative discovery program targeting opioid use disorder (OUD).  Short explained that the NIH grant review process is “highly competitive,” with independent experts assessing the novelty and potential impact of atai’s work.   He said this was the first time external reviewers had a chance to examine the company’s serotonergic 2A/2C agonists, compounds with non-ha ...